Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Alpha-tocopherol does not prevent hair loss from doxorubicin.

PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.

Krt15+ cells in mice can resist radiation, regenerate tissue, and start tumors, suggesting new cancer treatment targets.

Targeted anticancer therapies in children often cause skin side effects like rash and dry skin.

Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.

Hair dye may trigger anti-GBM disease relapse, and rituximab can help manage it.

Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.

Trilostane helped a dog with an adrenal tumor feel better and stay healthy.

The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.

Radiotherapy effectively treated a large scalp tumor in an elderly woman, avoiding surgery.

Cutaneous Lymphadenoma is a unique skin tumor with specific protein markers and common gene mutations that may cause continuous cell growth.

ZD1839 can cause skin issues like acne and hair changes.

Sporadic trichoblastic neoplasms generally don't recur or spread, with one case showing a specific genetic fusion.

Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

Vorasidenib can cause unusual hair growth.

Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.

Activating certain cells in hair follicles can prevent hair loss caused by cancer treatments.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Erlotinib can cause hair loss as a side effect.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

Combining Western chemotherapy with Traditional Chinese Medicine can reduce side effects and improve immune response in treating bone and soft tissue tumors.

Tacrolimus can cause hair loss in kidney transplant patients.